UWCCC Molecular Tumor Board Registry

NCT03023202 | Recruiting

• 8 other identifiers: 2015-1370P30CA0145201R37CA226526-01A1NCI-2019-06343A533400SMPH\UWCCC\GENERALProtocol Version 3/24/24UW15068
• Study Type: observational
• Target: 10,000
• Locations: 1 country
• Sites: 1

Brief Summary

This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.

Conditions

Hematologic Neoplasms; Solid Neoplasm

Outcome Measures

Primary Outcomes (2)

• Frequency of acceptance of molecular tumor board recommendations

  How often the molecular tumor board's recommendations are accepted

  Up to 5 years

• Benefit from PMMTB recommended treatment

  Whether patients benefit from PMMTB recommended treatment

  Up to 5 years

Secondary Outcomes (3)

• Correlation of mutations with protein overexpression

  Up to 5 years

• Correlations of mutations with circulating tumor DNA

  Up to 5 years

• Correlations of mutations with spheroid culture investigations

  Up to 5 years

Study Arms (1)

PMMTB

This study of the PMMTB will include all patients \>= 18 with clinically suspected or histologically confirmed solid or hematological malignancy who will undergo genetic testing of their tumor. All standard of care functions will be performed by standard procedures.

Other: PMMTB (Precision Medicine Molecular Tumor Board)

Interventions

PMMTB (Precision Medicine Molecular Tumor Board) OTHER

PMMTB is a clinical intervention, NOT a research intervention. The research component of this study is to observe the outcomes of the PMMTB.

PMMTB

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This study will include all patients age ≥18 with clinically suspected or histologically confirmed solid or hematological malignancy who will undergo genetic testing of their tumor. It will require each patient to have the ability to understand and willingness to sign a written informed consent document.

You may qualify if:

• Clinically suspected or histologically confirmed solid or hematological malignancy
• Undergoing genetic testing of tumor
• Ability to understand written informed consent document
• Willingness to sign written informed consent document

You may not qualify if:

• Pediatric patients (age\<18 years) will be excluded due to a lack of expertise on the molecular tumor committee

Sponsors & Collaborators

• University of Wisconsin, Madison: lead
• National Cancer Institute (NCI): collaborator

Study Sites (1)

University of Wisconsin Carbone Cancer Center

Madison, Wisconsin, 53792, United States

RECRUITING

Related Links

• UW Carbone Cancer Center Home Page

Biospecimen

Retention: SAMPLES WITH DNA

Subjects will be asked to give one blood sample and up to two tissue samples (one at diagnossi \& one at progression of treatment, which are both standard clinical procedures). * Drawing 8 tsp of blood at the first clinic visit, DNA extraction from this blood, additional testing on this blood. * Retention of residual tumor tissue for future research. * Collection of residual fresh tumor tissue \[that was biopsied for clinical reasons\], and performing of genetic analyses/retention for future research. * Banking of data, blood, and biopsy tissue for future research. * Distribution of banked data/blood/biopsied tissue for research projects.

MeSH Terms

Conditions

Hematologic Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases

Study Officials

• Dustin Deming, MD

  University of Wisconsin, Madison

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Cancer Connect

CONTACT

8006228922; clinicaltrials@cancer.wisc.edu

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 13, 2017
• First Posted: January 18, 2017
• Study Start: March 30, 2016
• Primary Completion (Estimated): March 1, 2029
• Study Completion (Estimated): March 1, 2029
• Last Updated: April 13, 2026

Record last verified: 2026-04

Locations

US (1)